TABLE II.
Comparison of Response Rates Between the Present Results and Those of Binder et al. [2004] at 2-Week Time Point
Responder |
Percent responder | Non-responder |
Percent non-responder | ||||||
---|---|---|---|---|---|---|---|---|---|
CC | CA | AA | CC | CA | AA | P-value | |||
rs3800373 | |||||||||
Combined | 9% (11) | 45% (56) | 46% (57) | 60% (124) | 9% (7) | 52% (42) | 40% (32) | 40% (81) | 0.627 |
Mirtazipine | 6% (4) | 49% (34) | 46% (32) | 63% (70) | 12% (5) | 59% (24) | 29% (12) | 37% (41) | 0.166 |
Paroxetine | 13% (7) | 41% (22) | 46% (25) | 57% (54) | 5% (2) | 45% (18) | 50% (20) | 43% (40) | 0.430 |
Max-Planck Institute of Psychiatry | 14% (21) | 33% (48) | 53% (77) | 63% (146) | 0% (0) | 41% (35) | 59% (51) | 37% (86) | 0.00003 |
Ludwig Maximillian University | 9% (4) | 53% (23) | 37% (16) | 51% (43) | 2% (1) | 36% (15) | 62% (26) | 49% (42) | 0.053 |
Responder |
Percent responder | Non-responder |
Percent non-responder | ||||||
---|---|---|---|---|---|---|---|---|---|
TT | CT | CC | TT | CT | CC | P value | |||
rsl360780 | |||||||||
Combined | 8% (10) | 48% (60) | 44% (54) | 60% (124) | 12% (10) | 51% (41) | 37% (30) | 40% (81) | 0.478 |
Mirtazipine | 4% (3) | 53% (37) | 43% (30) | 63% (70) | 15% (6) | 61% (25) | 24% (10) | 37% (41) | 0.046 |
Paroxetine | 13% (7) | 43% (23) | 44% (24) | 57% (54) | 10% (4) | 40% (16) | 50% (20) | 43% (40) | 0.835 |
Max-Planck Institute of Psychiatry | 15% (22) | 34% (50) | 51% (75) | 63% (147) | 1% (1) | 42% (36) | 57% (49) | 37% (86) | 0.00048 |
Ludwig Maximillian University | 12% (5) | 56% (24) | 33% (14) | 50% (43) | 5% (2) | 37% (16) | 58% (25) | 50% (43) | 0.02 |
Response is defined as a 25% reduction in HDRS-21 score. Results are given as percent responder or non-responder across rows, with the number of genotype carriers shown in parentheses. Binder et al. [2004] results are indicated by rows labeled as Max-Planck, Institute of Psychiatry, and Ludwig Maximillian University. The format of this table is modeled after that of Binder et al. [2004].